Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions
VRTX Stock Forecast
Vertex Pharmaceuticals stock forecast is as follows: an average price target of $381.05 (represents a -21.49% downside from VRTX’s last price of $485.37) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
VRTX Price Target
The average price target for Vertex Pharmaceuticals (VRTX) is $381.05 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $600.00 to $240.00. This represents a potential -21.49% downside from VRTX's last price of $485.37.
VRTX Analyst Ratings
According to 16 Wall Street analysts, Vertex Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for VRTX stock is 0 'Strong Buy' (0.00%), 11 'Buy' (68.75%), 5 'Hold' (31.25%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vertex Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 05, 2024 | Joon Lee | Truist Financial | $550.00 | $494.46 | 11.23% | 13.32% |
| Aug 05, 2024 | Hartaj Singh | Oppenheimer | $550.00 | $477.86 | 15.10% | 13.32% |
| Aug 05, 2024 | Andy Chen | Wolfe Research | $576.00 | $476.91 | 20.78% | 18.67% |
| Aug 02, 2024 | Andrew Fein | H.C. Wainwright | $600.00 | $505.78 | 18.63% | 23.62% |
| Jun 17, 2024 | Jasper Hellweg | Argus Research | $550.00 | $474.61 | 15.88% | 13.32% |
| Jun 11, 2024 | Brian Abrahams | RBC Capital | $421.00 | $483.28 | -12.89% | -13.26% |
| May 31, 2024 | Evan David Seigerman | BMO Capital | $500.00 | $443.05 | 12.85% | 3.01% |
| May 07, 2024 | Christopher Raymond | Raymond James | $456.00 | $413.42 | 10.30% | -6.05% |
| May 07, 2024 | Brian Abrahams | RBC Capital | $424.00 | $402.50 | 5.34% | -12.64% |
| Apr 11, 2024 | Andrew Fein | H.C. Wainwright | $462.00 | $397.58 | 16.20% | -4.81% |
The latest Vertex Pharmaceuticals stock forecast, released on Aug 05, 2024 by Joon Lee from Truist Financial, set a price target of $550.00, which represents a 11.23% increase from the stock price at the time of the forecast ($494.46), and a 13.32% increase from VRTX last price ($485.37).
Vertex Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 5 | 11 |
| Avg Price Target | - | $565.20 | $502.45 |
| Last Closing Price | $485.37 | $485.37 | $485.37 |
| Upside/Downside | -100.00% | 16.45% | 3.52% |
In the current month, the average price target of Vertex Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vertex Pharmaceuticals's last price of $485.37. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 05, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 05, 2024 | Wolfe Research | Outperform | Outperform | Hold |
| Aug 05, 2024 | Barclays | Overweight | Equal-Weight | Downgrade |
| Aug 02, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 31, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Jul 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 11, 2024 | UBS | Underperform | Underperform | Hold |
| Jul 11, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Jul 11, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jun 24, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Vertex Pharmaceuticals's last stock rating was published by Oppenheimer on Aug 05, 2024. The company gave VRTX a "Outperform" rating, the same as its previous rate.
Vertex Pharmaceuticals Financial Forecast
Vertex Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $2.48B | $2.49B | $2.37B | $2.30B | $2.33B | - | $2.10B | $2.07B | $1.98B | $1.79B | $1.72B | $1.63B | $1.54B | $1.52B | $1.52B | $1.41B | $949.83M | $941.29M | $858.43M | $870.11M | $784.53M |
| Avg Forecast | $3.03B | $2.94B | $2.84B | $2.74B | $2.75B | $2.69B | $2.66B | $2.58B | $2.51B | $2.50B | $2.42B | $2.34B | $2.30B | $2.23B | $2.13B | $2.07B | $2.00B | $1.86B | $1.72B | $1.66B | $1.59B | $1.49B | $1.39B | $1.30B | $1.01B | $950.95M | $886.16M | $851.35M | $709.47M | $734.12M |
| High Forecast | $3.08B | $2.99B | $2.89B | $2.79B | $2.80B | $2.74B | $2.71B | $2.63B | $2.56B | $2.58B | $2.46B | $2.38B | $2.34B | $2.27B | $2.13B | $2.12B | $2.05B | $1.90B | $1.76B | $1.70B | $1.63B | $1.52B | $1.43B | $1.33B | $1.04B | $973.34M | $907.02M | $871.39M | $851.37M | $880.94M |
| Low Forecast | $2.97B | $2.89B | $2.79B | $2.69B | $2.70B | $2.65B | $2.61B | $2.53B | $2.44B | $2.42B | $2.37B | $2.29B | $2.26B | $2.19B | $2.13B | $1.98B | $1.91B | $1.77B | $1.64B | $1.58B | $1.52B | $1.42B | $1.33B | $1.24B | $968.99M | $908.13M | $846.25M | $813.01M | $567.58M | $587.30M |
| # Analysts | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 1.03% | 1.02% | 1.00% | 1.05% | - | 1.01% | 1.03% | 1.07% | 1.04% | 1.04% | 1.02% | 1.04% | 1.09% | 1.17% | 1.39% | 1.00% | 1.06% | 1.01% | 1.23% | 1.07% |
Vertex Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 12 analysts is $2.51B, with a low forecast of $2.44B, and a high forecast of $2.56B. VRTX's average Quarter revenue forecast represents a 1.18% increase compared to the company's last Quarter revenue of $2.48B (Sep 23).
Vertex Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | - | $1.04B | $1.03B | $1.25B | $1.11B | $1.22B | - | $962.20M | $919.88M | $1.13B | $2.46M | $865.47M | $934.27M | $786.37M | $865.34M | $698.49M | $717.46M | $111.06M | $369.67M | $362.17M | $81.53M | $164.14M |
| Avg Forecast | $1.28B | $1.25B | $1.20B | $1.16B | $1.16B | $1.14B | $1.13B | $1.21B | $1.06B | $1.06B | $1.03B | $1.10B | $976.43M | $1.01B | $903.19M | $996.96M | $900.36M | $919.42M | $1.86M | $772.17M | $963.12M | $685.55M | $639.60M | $430.42M | $469.61M | $103.34M | $304.03M | $298.70M | $63.07M | $152.87M |
| High Forecast | $1.31B | $1.27B | $1.23B | $1.18B | $1.18B | $1.16B | $1.15B | $1.45B | $1.09B | $1.09B | $1.04B | $1.32B | $993.37M | $1.21B | $903.19M | $1.20B | $1.08B | $1.10B | $2.23M | $926.60M | $1.16B | $822.66M | $767.52M | $516.51M | $563.53M | $124.00M | $364.84M | $358.44M | $75.68M | $183.45M |
| Low Forecast | $1.26B | $1.22B | $1.18B | $1.14B | $1.14B | $1.12B | $1.11B | $965.05M | $1.03B | $1.03B | $1.01B | $877.32M | $957.39M | $809.09M | $903.19M | $797.56M | $720.29M | $735.54M | $1.49M | $617.73M | $770.50M | $548.44M | $511.68M | $344.34M | $375.69M | $82.67M | $243.22M | $238.96M | $50.45M | $122.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.98% | 1.00% | 1.14% | 1.14% | 1.20% | - | 0.97% | 1.02% | 1.23% | 1.32% | 1.12% | 0.97% | 1.15% | 1.35% | 1.62% | 1.53% | 1.07% | 1.22% | 1.21% | 1.29% | 1.07% |
12 analysts predict VRTX's average Quarter EBITDA for Dec 23 to be $1.06B, with a high of $1.09B and a low of $1.03B. This is 2.55% upper than Vertex Pharmaceuticals's previous annual EBITDA (Sep 23) of $1.04B.
Vertex Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 14 |
| Net Income | - | - | - | - | - | - | - | - | - | $1.04B | $915.70M | $699.80M | $818.90M | $930.50M | - | $762.10M | $770.11M | $851.93M | $66.92M | $653.14M | $604.19M | $667.43M | $837.27M | $602.75M | $583.23M | $57.52M | $267.43M | $268.63M | $1.55B | $128.75M |
| Avg Forecast | $1.38B | $1.37B | $1.25B | $1.20B | $1.04B | $1.04B | $-3.00B | $914.21M | $1.05B | $1.02B | $996.02M | $831.10M | $911.21M | $762.69M | $906.96M | $755.55M | $753.77M | $693.36M | $50.56M | $582.73M | $622.85M | $581.87M | $618.85M | $371.43M | $381.75M | $53.52M | $219.94M | $221.55M | $1.20B | $119.91M |
| High Forecast | $1.41B | $1.40B | $1.27B | $1.22B | $1.06B | $1.25B | $-2.92B | $1.10B | $1.14B | $1.12B | $1.02B | $997.32M | $931.75M | $915.23M | $906.96M | $906.66M | $904.53M | $832.03M | $60.68M | $699.27M | $747.42M | $698.24M | $742.62M | $445.71M | $458.10M | $64.22M | $263.93M | $265.86M | $1.44B | $143.89M |
| Low Forecast | $1.35B | $1.33B | $1.21B | $1.17B | $1.01B | $966.08M | $-3.07B | $731.37M | $949.36M | $852.03M | $970.78M | $664.88M | $888.12M | $610.15M | $906.96M | $604.44M | $603.02M | $554.69M | $40.45M | $466.18M | $498.28M | $465.49M | $495.08M | $297.14M | $305.40M | $42.81M | $175.95M | $177.24M | $959.57M | $95.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 0.92% | 0.84% | 0.90% | 1.22% | - | 1.01% | 1.02% | 1.23% | 1.32% | 1.12% | 0.97% | 1.15% | 1.35% | 1.62% | 1.53% | 1.07% | 1.22% | 1.21% | 1.29% | 1.07% |
Vertex Pharmaceuticals's average Quarter net income forecast for Dec 23 is $1.05B, with a range of $949.36M to $1.14B. VRTX's average Quarter net income forecast represents a 1.39% increase compared to the company's last Quarter net income of $1.04B (Sep 23).
Vertex Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 14 |
| SG&A | - | - | - | - | - | - | - | - | - | $263.80M | $262.60M | $241.10M | $267.40M | $246.80M | - | $215.20M | $255.16M | $198.19M | $194.67M | $192.08M | $211.84M | $184.55M | $191.80M | $182.26M | $195.28M | $159.67M | $156.50M | $147.04M | $153.21M | $137.29M |
| Avg Forecast | $372.52M | $361.66M | $349.39M | $337.23M | $337.90M | $330.43M | $327.39M | $258.15M | $308.85M | $307.46M | $297.52M | $234.69M | $283.28M | $177.43M | $262.03M | $213.35M | $249.75M | $161.30M | $147.08M | $171.37M | $218.39M | $160.89M | $141.77M | $112.31M | $127.82M | $148.57M | $128.71M | $121.27M | $118.52M | $127.87M |
| High Forecast | $378.98M | $367.93M | $355.44M | $343.07M | $343.76M | $336.60M | $333.07M | $309.78M | $315.03M | $316.90M | $302.68M | $281.62M | $288.20M | $212.92M | $262.03M | $256.02M | $299.70M | $193.56M | $176.50M | $205.64M | $262.06M | $193.07M | $170.12M | $134.77M | $153.38M | $178.28M | $154.45M | $145.53M | $142.23M | $153.45M |
| Low Forecast | $365.25M | $354.61M | $342.57M | $330.65M | $331.31M | $325.50M | $321.01M | $206.52M | $300.20M | $297.84M | $291.72M | $187.75M | $277.76M | $141.94M | $262.03M | $170.68M | $199.80M | $129.04M | $117.67M | $137.10M | $174.71M | $128.71M | $113.41M | $89.85M | $102.25M | $118.85M | $102.97M | $97.02M | $94.82M | $102.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.86% | 0.88% | 1.03% | 0.94% | 1.39% | - | 1.01% | 1.02% | 1.23% | 1.32% | 1.12% | 0.97% | 1.15% | 1.35% | 1.62% | 1.53% | 1.07% | 1.22% | 1.21% | 1.29% | 1.07% |
Vertex Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $308.85M, based on 12 Wall Street analysts, with a range of $300.20M to $315.03M. The forecast indicates a 17.08% rise compared to VRTX last annual SG&A of $263.80M (Sep 23).
Vertex Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 12 | 7 | 7 | 13 | 9 | 17 | 8 | 6 | 12 | 25 | 12 | 12 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 14 |
| EPS | - | - | - | - | - | - | - | - | - | $4.01 | $3.55 | $2.72 | $3.19 | $3.63 | - | $2.99 | $3.02 | $3.30 | $0.26 | $2.52 | $2.32 | $2.56 | $3.22 | $2.32 | $2.26 | $0.22 | $1.04 | $1.05 | $6.08 | $0.51 |
| Avg Forecast | $5.36 | $5.31 | $4.83 | $4.63 | $4.03 | $4.05 | $-11.63 | $4.07 | $4.07 | $3.93 | $3.86 | $3.01 | $3.53 | $3.61 | $3.47 | $3.57 | $3.29 | $3.09 | $2.53 | $2.70 | $2.57 | $2.35 | $2.08 | $1.87 | $1.21 | $1.15 | $1.07 | $1.01 | $0.82 | $0.95 |
| High Forecast | $5.48 | $5.43 | $4.93 | $4.74 | $4.12 | $4.83 | $-11.33 | $4.16 | $4.42 | $4.34 | $3.95 | $3.08 | $3.61 | $3.69 | $3.47 | $3.68 | $3.39 | $3.18 | $2.61 | $2.78 | $2.65 | $2.42 | $2.15 | $1.92 | $1.25 | $1.19 | $1.10 | $1.04 | $0.98 | $1.14 |
| Low Forecast | $5.22 | $5.17 | $4.70 | $4.52 | $3.93 | $3.74 | $-11.89 | $3.97 | $3.68 | $3.30 | $3.76 | $2.94 | $3.44 | $3.52 | $3.47 | $3.36 | $3.09 | $2.91 | $2.38 | $2.54 | $2.42 | $2.21 | $1.96 | $1.76 | $1.14 | $1.09 | $1.01 | $0.95 | $0.66 | $0.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 0.92% | 0.90% | 0.90% | 1.00% | - | 0.84% | 0.92% | 1.07% | 0.10% | 0.93% | 0.90% | 1.09% | 1.55% | 1.24% | 1.86% | 0.19% | 0.97% | 1.04% | 7.41% | 0.54% |
According to 12 Wall Street analysts, Vertex Pharmaceuticals's projected average Quarter EPS for Dec 23 is $4.07, with a low estimate of $3.68 and a high estimate of $4.42. This represents a 1.42% increase compared to VRTX previous annual EPS of $4.01 (Sep 23).
Vertex Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics | $22.07 | $119.16 | 439.92% | Buy |
| EDIT | Editas Medicine | $3.95 | $17.00 | 330.38% | Buy |
| VERV | Verve Therapeutics | $5.50 | $21.50 | 290.91% | Buy |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| CRSP | CRISPR Therapeutics | $48.94 | $109.58 | 123.91% | Buy |
| MRNA | Moderna | $68.28 | $148.85 | 118.00% | Hold |
| VKTX | Viking Therapeutics | $66.73 | $100.50 | 50.61% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| SRPT | Sarepta Therapeutics | $124.65 | $169.93 | 36.33% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| PTCT | PTC Therapeutics | $33.99 | $44.33 | 30.42% | Hold |
| BNTX | BioNTech SE | $123.40 | $149.23 | 20.93% | Buy |
| DNA | Ginkgo Bioworks | $6.32 | $7.34 | 16.14% | Buy |
| KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| REGN | Regeneron Pharmaceuticals | $1.15K | $952.23 | -17.44% | Buy |
| VRTX | Vertex Pharmaceuticals | $485.37 | $381.05 | -21.49% | Buy |
VRTX Forecast FAQ
Is Vertex Pharmaceuticals a good buy?
Yes, according to 16 Wall Street analysts, Vertex Pharmaceuticals (VRTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 68.75% of VRTX's total ratings.
What is VRTX's price target?
Vertex Pharmaceuticals (VRTX) average price target is $381.05 with a range of $240 to $600, implying a -21.49% from its last price of $485.37. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vertex Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for VRTX stock, the company can go down by -21.49% (from the last price of $485.37 to the average price target of $381.05), up by 23.62% based on the highest stock price target, and down by -50.55% based on the lowest stock price target.
Can Vertex Pharmaceuticals stock reach $700?
VRTX's average twelve months analyst stock price target of $381.05 does not support the claim that Vertex Pharmaceuticals can reach $700 in the near future.
What are Vertex Pharmaceuticals's analysts' financial forecasts?
Vertex Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $10.68B (high $10.87B, low $10.49B), average EBITDA is $4.64B (high $4.94B, low $4.34B), average net income is $-497K (high $482.71M, low $-356M), average SG&A $1.25B (high $1.32B, low $1.18B), and average EPS is $0.529 (high $1.78, low $-0.244). VRTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $11.56B (high $11.76B, low $11.33B), average EBITDA is $4.9B (high $4.98B, low $4.8B), average net income is $5.19B (high $5.31B, low $5.06B), average SG&A $1.42B (high $1.45B, low $1.39B), and average EPS is $20.12 (high $20.57, low $19.61).
Did the VRTX's actual financial results beat the analysts' financial forecasts?
Based on Vertex Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $8.93B, beating the average analysts forecast of $8.74B by 2.16%. Apple's EBITDA was $4.35B, beating the average prediction of $3.89B by 11.76%. The company's net income was $3.32B, missing the average estimation of $3.34B by -0.43%. Apple's SG&A was $944.7M, beating the average forecast of $936.1M by 0.92%. Lastly, the company's EPS was $12.97, missing the average prediction of $14.19 by -8.57%. In terms of the last quarterly report (Sep 2023), Vertex Pharmaceuticals's revenue was $2.48B, missing the average analysts' forecast of $2.5B by -0.72%. The company's EBITDA was $1.04B, missing the average prediction of $1.06B by -2.04%. Vertex Pharmaceuticals's net income was $1.04B, beating the average estimation of $1.02B by 1.97%. The company's SG&A was $263.8M, missing the average forecast of $307.46M by -14.20%. Lastly, the company's EPS was $4.01, beating the average prediction of $3.93 by 1.94%